Supporting Information

Direct Radical Alkylation and Acylation of 2H-indazoles Using

Substituted Hantzsch Esters as Radical Reservoirs

Li Liu,^a Pengxing Jiang,^a Yongguo Liu,^b Hongguang Du,^{*a} and Jiajing Tan^{*a}

^aDepartment of Organic Chemistry, College of Chemistry, Beijing University of Chemical Technology (BUCT), Beijing 100029, China. E-mail: dhg@mail.buct.edu.cn; tanjj@mail.buct.edu.cn.

^bBeijing Key Laboratory of Flavour Chemistry, Beijing Technology and Business University (BTBU), Beijing 100048, China.

Contents

| 1. | General Methods | 3 |
|----|--|----|
| 2. | General Procedure A for the Alkylation of 2 <i>H</i> -indazoles | 6 |
| 3. | General procedure B for the Acylation of 2 <i>H</i> -indazoles | 7 |
| 4. | Scale-up Synthesis | 29 |
| 5. | Synthesis of Bioactive Molecules | 30 |
| 6. | Control Experiment | 33 |
| 7. | References | 34 |
| 8. | ¹ H NMR and ¹³ C NMR Spectra of the Products | 35 |

1. General Methods

All reactions were carried out in schlenk tubes. The reactions were monitored by thin-layer chromatography on silica gel 60-F254 coated 0.2 mm plates. Visualization was accomplished by UV light (254 nm). The crude products were purified by flash column chromatography using silica gel (normal phase, 200-300 mesh. ¹H NMR spectra were recorded on a 400 MHz spectrometer at ambient temperature. Data were reported as follows: (1) chemical shift in parts per million (δ , ppm) from CDCl₃ (7.26 ppm), DMSO-*d*₆ (2.50 ppm); (2) multiplicity (s = singlet, br = broad, d = doublet, t = triplet, q = quartet, and m = multiplet); (3) coupling constants (Hz). ¹³C NMR spectra were recorded on a 100 MHz spectrometer at ambient temperature. Chemical shifts were reported in ppm from CDCl₃ (77.10 ppm), DMSO-*d*₆ (39.52 ppm). Melting points were obtained on a melting point apparatus and the data are uncorrected. HR-MS analyses were carried out using a time-of-flight (TOF)-MS instrument with an electrospray ionization (ESI) source. All commercial materials were used as received unless otherwise noted.

1.1 Synthesis of 2*H*-indazoles



Figure S1 2*H*-indazoles used in this study

Compounds $1^{[1,2]}$, 2-8^[2], 9-11^[1], 12-14^[2], 15-16^[1,2]were synthesized via reported procedures.

1.2 Synthesis of 1,4-Dihydropyridines



Figure S2 Hantzsch esters used in this study

Compounds $17-19^{[3]}$, $20^{[5]}$ $21-24^{[3]}$, $25^{[4]}$, $26-33^{[6]}$ were synthesized via reported procedures.

Table S1. Optimization studies^a



| 2 | AgNO ₃ | $Na_2S_2O_8$ | TFA | DMSO:H ₂ O=1:1 | 45% |
|-----------------|-------------------|------------------|-----|-------------------------------------|-------------------------|
| 3 | AgNO ₃ | $Na_2S_2O_8$ | TFA | <i>i</i> -PrOH:H ₂ O=1:1 | 61% |
| 4 | AgNO ₃ | $(NH_4)_2S_2O_8$ | TFA | acetone:H ₂ O=1:1 | 60% |
| 5 | AgNO ₃ | $K_2S_2O_8$ | TFA | acetone:H ₂ O=1:1 | 50% |
| 6 ^c | AgNO ₃ | $Na_2S_2O_8$ | TFA | acetone:H ₂ O=1:1 | 54% |
| 7^d | AgNO ₃ | $Na_2S_2O_8$ | TFA | acetone:H ₂ O=1:1 | 55% |
| 8 ^e | AgNO ₃ | $Na_2S_2O_8$ | TFA | acetone:H ₂ O=1:1 | 68% |
| 9ſ | AgNO ₃ | $Na_2S_2O_8$ | TFA | acetone:H ₂ O=1:1 | 85% |
| 10 ^g | AgNO ₃ | $Na_2S_2O_8$ | TFA | acetone:H ₂ O=1:1 | 79% |
| 11^{h} | AgNO ₃ | $Na_2S_2O_8$ | TFA | acetone:H ₂ O=1:1 | 82% |
| 12^{i} | AgNO ₃ | $Na_2S_2O_8$ | TFA | acetone:H ₂ O=1:1 | 56% |
| 13 ^j | AgNO ₃ | $Na_2S_2O_8$ | TFA | acetone:H ₂ O=1:1 | 88%(87% ^k) |
| | | | | | |

^{*a*}Reaction conditions: **1a** (0.10 mmol), **4a** (0.30 mmol), catalyst (0.03 mmol), oxidant (0.30 mmol) and acid (0.30 mmol) in solvents (v/v = 1:1, 0.1 M) were stirred under N₂ atmosphere for 10 h, RT. ^{*b*}Yield was determined by ¹H NMR. ^{*c*}1 equiv. Na₂S₂O₈ used. ^{*d*}2 equiv. Na₂S₂O₈ used. ^{*d*}2 equiv. Na₂S₂O₈ used. ^{*d*}2 equiv. Na₂S₂O₈ used. ^{*d*}2 equiv. Na₂S₂O₈ used. ^{*f*}25 °C, 4 h. ^{*g*}30 °C, 4 h. ^{*h*}40 °C, 4 h. ^{*i*}80 °C, 4 h. ^{*j*}0.4 equiv. AgNO₃ used, 25 °C, 4 h. ^{*k*}Isolated yields.

2. General Procedure A for the Alkylation of 2H-indazoles



The reaction vessel was charged with 2*H*-indazole (**1a**, 0.2 mmol, 39 mg), alkyl-DHP reagent (**2a**, 0.6 mmol, 177 mg), Na₂S₂O₈ (3.0 equiv., 143 mg), AgNO₃ (30 mol%, 10 mg) and TFA (2.0 equiv., 46 mg) in *i*-PrOH/H₂O (1:1, 4 mL), and the reaction mixture was stirred under nitrogen atmosphere at room temperature for 2 h. After completion, the reaction mixture was quenched with 20 mL water/ethyl acetate (1:1). Then the reaction mixture was extracted with ethyl acetate and the organic phase was washed with brine, dried over anhydrous Na₂SO₄. After evaporating the solvent under reduced pressure, the crude product was purified by column chromatography using petroleum ether/ethyl acetate as the eluents.

When the diethyl 2,6-dimethylpyridine-3,5-dicarboxylate byproduct had a Rf similar to that of products **3**, the pyridine was removed by dissolving the crude product in methyl tert-butyl ether (10 mL) and washing the organic layer with HCl (1 mL) prior to purification by column chromatography.



Figure S3 Alkylation of 2*H*-indazoles by 4- primary alkylated DHPs

Unfortunately, primary alkyl radicals did not deliver the expected product because the corresponding DHP does not undergo homolytic C-C cleavage but rather C-H homolysis, resulting in the formation of a 4-alkylated pyridine byproduct (**3aa-3ab**). When 4-benzyl-DHP was used, the produce of **3ac** was low in 8% yield.

3. General procedure B for the Acylation of 2H-indazoles



The reaction vessel was charged with 2*H*-indazole (**1a**, 0.2 mmol, 39 mg), acyl-DHP reagent (**4a**, 0.6 mmol, 222 mg), Na₂S₂O₈ (3.0 equiv., 143 mg), AgNO₃ (40 mol%, 14 mg) and TFA (3.0 equiv., 68 mg) in acetone/H₂O (1:1, 4 mL), and the reaction mixture was stirred under nitrogen atmosphere at 25 °C for 4 h. After completion, the reaction mixture was quenched with 20 mL water/ethyl acetate (1:1). Then the reaction mixture was extracted with ethyl acetate and the organic phase was washed with brine, dried over anhydrous Na₂SO₄. After evaporating the solvent under reduced pressure, the crude product was purified by column chromatography using petroleum ether/ethyl acetate as the eluents.



3-isopropyl-2-phenyl-2H-indazole (3a)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=20:1 as the eluent) to give **3a** (43 mg, 92% yield) as a yellow solid. Compound is known.

¹**H NMR** (400 MHz, CDCl₃) δ 7.84 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.55-7.47 (m, 5H), 7.30 (ddd, J = 8.7, 6.6, 0.9 Hz, 1H), 7.05 (ddd, J = 8.5, 6.6, 0.7 Hz, 1H), 3.36 (hept, J = 7.1 Hz, 1H), 1.48 (d, J = 7.1 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 148.9, 142.0, 140.2, 129.2, 129.1, 126.5, 126.4, 121.0, 120.7, 119.2, 117.9, 27.1, 22.5.

HRMS (ESI): Calcd for C₁₆H₁₇N₂ ⁺ [M+H]⁺ 237.1386, found 237.1380.



3-isopropyl-2-(p-tolyl)-2H-indazole (3b)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3b** (39 mg, 78% yield) as a yellow solid. New compounds.

¹**H** NMR (400 MHz, CDCl₃) δ 7.83 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.36-7.26 (m, 5H), 7.05-7.01 (m, 1H), 3.35 (hept, J = 7.0 Hz, 1H), 2.45 (s, 3H), 1.47 (d, J = 7.0 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 148.8, 141.9, 139.1, 137.6, 129.7, 126.6, 120.9, 120.5, 119.0, 117.8, 27.1, 22.4, 21.2.

HRMS (ESI): Calcd for $C_{17}H_{19}N_2^+$ [M+H]⁺ 251.1543, found 251.1435.



3-isopropyl-2-(m-tolyl)-2H-indazole (3c)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3c** (44 mg, 89% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.83 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 7.32-7.24 (m, 4H), 7.06-7.02 (m, 1H), 3.37 (hept, J = 7.0 Hz, 1H),

2.44 (s, 3H), 1.48 (d, J = 7.0 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 148.8, 141.8, 140.0, 139.4, 129.8, 128.8, 127.1, 126.2, 123.4, 120.9, 120.5, 119.1, 117.8, 27.1, 22.5, 21.3.

HRMS (ESI): Calcd for $C_{17}H_{19}N_2^+$ [M+H]⁺ 251.1543, found 251.1436.



3-isopropyl-2-(4-methoxyphenyl)-2H-indazole (3d)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3d** (50 mg, 95% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.86 (d, J = 8.5 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.44-7.40 (m, 2H), 7.32 (ddd, J = 8.7, 6.6, 0.9 Hz, 1H), 7.09-7.03 (m, 3H), 3.91 (s, 3H), 3.36 (hept, J = 7.1 Hz, 1H), 1.50 (d, J = 7.1 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 160.0, 148.7, 142.1, 133.1, 127.6, 126.2, 120.9, 120.5, 119.0, 117.8, 114.2, 55.6, 27.1, 22.4.

HRMS (ESI): Calcd for C₁₇H₁₉N₂O⁺ [M+H]⁺ 267.1492, found 267.1488.



3-isopropyl-2-(4-(trifluoromethyl)phenyl)-2H-indazole (3e)

Following the general procedure A, the crude product was purified by silica gel flash

chromatography (PE: EA=15:1 as the eluent) to give **3e** (28 mg, 47% yield) as a yellow solid. New compounds.

¹**H** NMR (400 MHz, CDCl₃) δ 7.85-7.81 (m, 3H), 7.71 (d, J = 8.8 Hz, 1H), 7.65 (d, J = 8.2 Hz, 2H), 7.32 (ddd, J = 8.8, 6.6, 0.9 Hz, 1H), 7.07 (ddd, J = 8.5, 6.6, 0.8 Hz, 1H), 3.37 (hept, J = 7.0 Hz, 1H), 1.51 (d, J = 7.0 Hz, 6H).

¹³**C NMR** (100 MHz, CDCl₃) δ 149.3, 143.1, 142.1, 131.2(q, *J* = 32.8 Hz, 1C), 127.0, 126.9, 126.5(q, *J* = 3.7 Hz, 1C), 123.8(q, *J* = 270.8 Hz, 1C), 121.1, 121.0, 119.5, 118.0, 27.2, 22.6.

HRMS (ESI): Calcd for $C_{17}H_{16}F_3N_2^+$ [M+H]⁺ 305.1260, found 305.1259.



2-(4-chlorophenyl)-3-isopropyl-2H-indazole (3f)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3f** (37 mg, 70% yield) as a yellow solid. New compounds.

¹**H** NMR (400 MHz, CDCl₃) δ 7.82 (d, J = 8.6 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.53-7.49 (m, 2H), 7.44-7.41 (m, 2H), 7.30 (ddd, J = 8.7, 6.6, 0.9 Hz, 1H), 7.05 (ddd, J = 8.4, 6.6, 0.8 Hz, 1H), 3.33 (hept, J = 7.0 Hz, 1H), 1.48 (d, J = 7.0 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 149.0, 142.0, 138.6, 135.0, 129.3, 127.7, 126.6, 120.9, 120.8, 119.2, 117.8, 27.1, 22.4.

HRMS (ESI): Calcd for C₁₆H₁₆ClN₂⁺[M+H]⁺ 271.0997, found 271.0994.



2-(4-bromophenyl)-3-isopropyl-2H-indazole (3g)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give 3g (44 mg, 71% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.82 (d, J = 8.6 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.66 (d, J = 8.5 Hz, 2H), 7.37 (d, J = 8.5 Hz, 2H), 7.32 -7.28 (m, 1H), 7.07-7.03 (m, 1H), 3.33 (hept, J = 7.0 Hz, 1H), 1.48 (d, J = 7.0 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 149.0, 142.0, 139.1, 132.3, 128.0, 126.6, 123.0, 120.9, 120.9, 119.2, 117.8, 27.1, 22.5.

HRMS (ESI): Calcd for C₁₆H₁₆BrN₂⁺[M+H]⁺ 315.0491, found 315.0484.



2-(3-chlorophenyl)-3-isopropyl-2H-indazole (3h)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3h** (36 mg, 67% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.83 (d, J = 8.6 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.53-7.44 (m, 3H), 7.38 (dt, J = 6.9, 1.9 Hz, 1H), 7.31 (ddd, J = 8.7, 6.6, 1.0 Hz, 1H), 7.06 (ddd, J = 8.5, 6.6, 0.8 Hz, 1H), 3.36 (hept, J = 7.0 Hz, 1H), 1.50 (d, J = 7.0 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 149.0, 142.0, 141.1, 134.9, 130.1, 129.2, 126.9, 126.7, 124.6, 120.9, 120.9, 119.2, 117.9, 27.1, 22.5.

HRMS (ESI): Calcd for C₁₆H₁₆ClN₂⁺[M+H]⁺ 271.0997, found 271.0994.



5-bromo-3-isopropyl-2-phenyl-2H-indazole (3i)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3i** (40 mg, 64% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.98 (d, J = 1.2 Hz, 1H), 7.60-7.45(m, 6H), 7.34 (dd, J = 9.1, 1.8 Hz, 1H), 3.33 (hept, J = 7.0 Hz, 1H), 1.45 (d, J = 7.1 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 147.3, 141.7, 139.8, 130.0, 129.3, 129.3, 126.4, 123.0, 120.3, 119.7, 114.0, 27.1, 22.5.

HRMS (ESI): Calcd for C₁₆H₁₆BrN₂⁺ [M+H]⁺ 315.0491, found 315.0490.



3-isopropyl-6-methoxy-2-phenyl-2H-indazole(3j)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3j** (37 mg, 71% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.69 (d, J = 9.2 Hz, 1H), 7.53-7.46 (m, 5H), 6.95 (d, J = 1.8 Hz, 1H), 6.75 (dd, J = 9.2, 2.1 Hz, 1H), 3.87 (s, 3H), 3.32 (hept, J = 7.0 Hz, 1H), 1.45 (d, J = 7.0 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 159.0, 150.0, 142.2, 140.2, 129.1, 128.8, 126.5, 121.8, 115.7, 114.9, 94.6, 55.3, 27.0, 22.5.

HRMS (ESI): Calcd for $C_{17}H_{19}N_2O^+$ [M+H]⁺ 267.1492, found 267.1483.



3-isopropyl-6-methyl-2-phenyl-2H-indazole(3k)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3k** (49 mg, 99% yield) as a yellow solid. New compounds.

¹**H** NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 8.7 Hz, 1H), 7.54-7.45 (m, 6H), 6.89 (dd, J = 8.7, 0.8 Hz, 1H), 3.33 (hept, J = 7.0 Hz, 1H), 2.45 (s, 3H), 1.46 (d, J = 7.0 Hz, 6H).

¹³**C NMR** (100 MHz, CDCl₃) *δ* 149.5, 141.8, 140.2, 136.2, 129.1, 128.9, 126.5, 123.5, 120.4, 117.5, 116.1, 27.0, 22.5, 22.1.

HRMS (ESI): Calcd for $C_{17}H_{19}N_2^+$ [M+H]⁺ 251.1543, found 251.1535.



2-hexyl-3-isopropyl-2H-indazole(3l)

Following the general procedure A, the crude product was purified by silica gel flash

chromatography (PE: EA=15:1 as the eluent) to give **31** (22 mg, 45% yield) as a yellow oil. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.75 (d, J = 8.5 Hz, 1H), 7.64 (d, J = 8.7 Hz, 1H), 7.24-7.20 (m, 1H), 6.97 (dd, J = 8.0, 7.1 Hz, 1H), 4.35 (t, J = 7.5 Hz, 2H), 3.42 (hept, J = 7.0 Hz, 1H), 1.97-1.89 (m, 2H), 1.52 (d, J = 7.0 Hz, 6H), 1.38-1.28 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 148.0, 140.1, 125.5, 120.7, 119.9, 119.0, 117.4, 50.8, 31.5, 31.1, 27.0, 26.6, 22.5, 22.4, 14.0.

HRMS (ESI): Calcd for $C_{16}H_{25}N_2^+$ [M+H]⁺ 245.2012, found 245.2006.



2-cyclohexyl-3-isopropyl-2H-indazole (3m)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3m** (20 mg, 42% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.75 (d, J = 8.5 Hz, 1H), 7.68 (d, J = 8.7 Hz, 1H), 7.21 (ddd, J = 8.7, 6.6, 1.0 Hz, 1H), 6.97 (ddd, J = 8.4, 6.6, 0.8 Hz, 1H), 4.35 (tt, J = 11.7, 3.7 Hz, 1H), 3.49 (hept, J = 7.0 Hz, 1H), 2.25-2.14 (m, 2H), 1.99-1.94 (m, 4H), 1.80-1.75 (m, 1H), 1.52 (d, J = 7.1 Hz, 6H), 1.48-1.34 (m, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 147.8, 139.3, 125.2, 120.8, 119.9, 118.8, 117.5, 59.0, 33.6, 26.7, 25.9, 25.2, 22.5.

HRMS (ESI): Calcd for $C_{16}H_{23}N_2^+$ [M+H]⁺ 243.1856, found 243.1855.



3-(sec-butyl)-2-phenyl-2H-indazole (3n)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3n** (21 mg, 43% yield) as a yellow oil. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.79 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.55-7.45 (m, 5H), 7.32-7.28 (m, 1H), 7.04 (dd, J = 7.9, 7.1 Hz, 1H), 3.13-3.03 (m, 1H), 2.03-1.92 (m, 1H), 1.85-1.74 (m, 1H), 1.46 (d, J = 7.1 Hz, 3H), 0.76 (t, J = 7.4 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 148.9, 141.2, 140.2, 129.1, 129.1, 126.8, 126.4, 120.9, 120.6, 119.1, 117.9, 34.2, 29.8, 20.6, 12.5.

HRMS (ESI): Calcd for $C_{17}H_{19}N_2^+$ [M+H]⁺ 251.1543, found 251.1546.



3-(pentan-3-yl)-2-phenyl-2H-indazole (30)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **30** (33 mg, 62% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.77 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.54-7.44 (m, 5H), 7.30 (ddd, J = 8.7, 6.6, 0.9 Hz, 1H), 7.03 (ddd, J = 8.4, 6.6, 0.7 Hz,

1H), 2.92-2.84 (m, 1H), 2.00-1.78 (m, 4H), 0.77 (t, *J* = 7.4 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 148.9, 140.3, 140.2, 129.1, 129.0, 127.3, 126.4, 120.9, 120.6, 119.1, 117.9, 41.5, 28.2, 12.6.

HRMS (ESI): Calcd for C₁₈H₂₁N₂⁺[M+H]⁺ 265.1699, found 265.1691.



3-cyclopentyl-2-phenyl-2H-indazole (3p)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3p** (42 mg, 81% yield) as a yellow oil. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.75 (d, J = 8.6 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.55-7.48 (m, 5H), 7.31-7.28 (m, 1H), 7.06-7.02 (m, 1H), 3.36 (p, J = 9.1 Hz, 1H), 2.12-2.07 (m, 4H), 2.00-1.90 (m, 2H), 1.74-1.67 (m, 2H).

¹³C NMR (100 MHz, CDCl₃) δ 149.0, 140.5, 140.3, 129.2, 128.9, 126.5, 126.4, 120.8, 120.6, 119.0, 118.0, 37.7, 33.5, 26.4.

HRMS (ESI): Calcd for $C_{18}H_{19}N_2^+$ [M+H]⁺ 263.1543, found 263.1534.



3-cyclohexyl-2-phenyl-2H-indazole (3q)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give 3q (41 mg, 74% yield) as a white solid. Compound is known.

¹**H NMR** (400 MHz, CDCl₃) δ 7.86 (d, *J* = 8.6 Hz, 1H), 7.71 (d, *J* = 8.7 Hz, 1H), 7.54-7.45 (m, 5H), 7.30-7.26 (m, 1H), 7.03 (dd, *J* = 8.1, 7.1 Hz, 1H), 2.97 (tt, *J* = 11.6, 4.3 Hz, 1H), 2.03-1.90 (m, 4H), 1.85-1.82 (m, 2H), 1.76-1.73 (m, 1H), 1.41-1.19 (m, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 148.9, 141.1, 140.2, 129.1, 128.9, 126.4, 126.3, 121.2, 120.5, 119.5, 117.8, 37.3, 32.6, 26.6, 25.9.

HRMS (ESI): Calcd for $C_{19}H_{21}N_2^+$ [M+H]⁺ 277.1699, found 277.1692.



2-phenyl-3-(tetrahydro-2H-pyran-4-yl)-2H-indazole (3r)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3r** (30 mg, 55% yield) as a yellow

solid. New compounds.

¹**H** NMR (400 MHz, CDCl₃) δ 7.88 (d, *J* = 8.6 Hz, 1H), 7.73 (d, *J* = 8.8 Hz, 1H), 7.57-7.45 (m, 5H), 7.33 -7.29 (m, 1H), 7.08 (dd, *J* = 8.0, 7.1 Hz, 1H), 4.07 (dd, *J* = 11.6, 4.1 Hz, 2H), 3.40 (t, *J* = 11.4 Hz, 2H), 3.23 (tt, *J* = 12.3, 3.8 Hz, 1H), 2.38 (qd, *J* = 12.7, 4.4 Hz, 2H), 1.78 (dd, *J* = 13.2, 1.8 Hz, 2H).

¹³C NMR (100 MHz, CDCl₃) δ 148.9, 140.0, 138.9, 129.3, 129.3, 126.5, 126.4, 121.1, 120.8, 119.6, 118.0, 68.1, 34.6, 32.1.

HRMS (ESI): Calcd for C₁₈H₁₉N₂O⁺ [M+H]⁺ 279.1492, found 279.1483.



3-(6-methylhept-5-en-2-yl)-2-phenyl-2H-indazole (3s)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3s** (39 mg, 65% yield) as a yellow oil. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.80 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.54-7.45 (m, 5H), 7.31-7.27 (m, 1H), 7.04 (dd, J = 7.9, 7.1 Hz, 1H), 4.89-4.88 (m, 1H), 3.24-3.15 (m, 1H), 2.03-1.97 (m, 1H), 1.84-1.76 (m, 3H), 1.56 (s, 3H), 1.46 (d, J = 7.0 Hz, 3H), 1.41 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 148.9, 141.1, 140.1, 132.2, 129.1, 129.0, 126.7, 126.3, 123.4, 120.8, 120.6, 119.2, 117.9, 36.6, 31.8, 26.1, 25.6, 20.7, 17.6.

HRMS (ESI): Calcd for $C_{21}H_{25}N_2^+$ [M+H]⁺ 305.2012, found 305.2004.



3-(1-(4-isopropylphenyl)propan-2-yl)-2-phenyl-2H-indazole(3t)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **3t** (45 mg, 64% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.90 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.40-7.36 (m, 1H), 7.333-7.30 (m, 3H), 7.12-7.08 (m, 1H), 6.95 (d, J = 8.0 Hz, 2H), 6.84 (d, J = 7.4 Hz, 2H), 6.63 (d, J = 8.0 Hz, 2H), 3.35-3.26 (m, 1H), 3.20 (dd, J = 12.9, 9.7 Hz, 1H), 2.95 (dd, J = 12.9, 5.5 Hz, 1H), 2.84 -2.77 (m, 1H), 1.54 (d, J = 7.0 Hz, 3H), 1.19 (dd, J = 6.9, 1.7 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 148.8, 146.9, 140.1, 139.7, 136.9, 128.9, 128.7, 128.6, 126.7, 126.3, 126.2, 120.8, 119.2, 118.0, 42.7, 35.5, 33.7, 24.1, 24.0, 20.7.

HRMS (ESI): Calcd for $C_{25}H_{27}N_2^+$ [M+H]⁺ 355.2169, found 355.2160.



3-(tert-butyl)-2-phenyl-2H-indazole(3u)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give 3u (32 mg, 65% yield) as a white solid. Compound is known.

¹**H** NMR (400 MHz, CDCl₃) δ 7.95 (d, J = 8.8 Hz, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.51-7.41 (m, 5H), 7.30-7.28(m, 1H), 7.06-7.02 (m, 1H), 1.43 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 148.4, 144.4, 142.9, 129.4, 128.4, 128.1, 125.9, 122.6, 120.7, 119.7, 117.8, 34.7, 31.8.

HRMS (ESI): Calcd for $C_{17}H_{19}N_2^+$ [M+H]⁺ 251.1543, found 251.1536.



(2-phenyl-2H-indazol-3-yl)(p-tolyl)methanone (5a)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5a** (54 mg, 87% yield) as a yellow solid. Compound is known.

¹**H NMR** (400 MHz, CDCl₃) δ 7.88 (d, J = 9.0 Hz, 1H), 7.80 (d, J = 8.1 Hz, 2H), 7.55-7.53 (m, 2H), 7.44-7.35 (m, 5H), 7.26 (d, J = 8.2 Hz, 2H), 7.16 (dd, J = 8.2, 7.4 Hz, 1H), 2.43 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 185.7, 148.5, 144.7, 140.5, 135.2, 132.5, 130.2, 129.4, 129.1, 128.9, 127.0, 125.5, 124.8, 123.9, 120.7, 118.5, 21.8.

HRMS (ESI): Calcd for $C_{21}H_{17}N_2O^+[M+H]^+$ 313.1335, found 313.1328.



p-tolyl(2-(p-tolyl)-2H-inden-1-yl)methanone (5b)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5b** (60 mg, 92% yield) as a white solid. New compounds.

¹**H** NMR (400 MHz, CDCl₃) δ 7.87 (d, J = 8.7 Hz, 1H), 7.81 (d, J = 8.2 Hz, 2H), 7.42

(d, *J* = 8.3 Hz, 2H), 7.37-7.33 (m, 2H), 7.27 (d, *J* = 8.0 Hz, 2H), 7.22 (d, *J* = 8.1 Hz, 2H), 7.16 -7.12 (m, 1H), 2.44 (s, 3H), 2.38 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 185.7, 148.4, 144.7, 138.9, 138.1, 135.2, 132.3, 130.2, 129.7, 129.4, 126.8, 125.2, 124.6, 123.8, 120.6, 118.4, 21.8, 21.2.

HRMS (ESI): Calcd for C₂₄H₂₁O⁺ [M+H]⁺ 327.1492, found 327.1491.



(2-(4-methoxyphenyl)-2H-indazol-3-yl)(p-tolyl)methanone (5c)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5c** (63 mg, 92% yield) as a white solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.86 (d, *J* = 8.7 Hz, 1H), 7.80 (d, *J* = 7.8 Hz, 2H), 7.46 (d, *J* = 8.6 Hz, 2H), 7.38-7.34 (m, 2H), 7.27 (d, *J* = 8.3 Hz, 2H), 7.17-7.13 (m, 1H), 6.93 (d, *J* = 8.6 Hz, 2H), 3.82 (s, 3H), 2.45 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 185.7, 159.8, 148.3, 144.7, 135.3, 133.6, 132.3, 130.2, 129.3, 126.8, 126.6, 124.6, 123.7, 120.6, 118.3, 114.2, 55.5, 21.8.

HRMS (ESI): Calcd for C₂₁H₁₇N₂O⁺ [M+H]⁺343.1441, found 343.1433



(2-(4-bromophenyl)-2H-indazol-3-yl)(p-tolyl)methanone (5d)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5d** (67 mg, 86% yield) as a white solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.86 (d, *J* = 8.8 Hz, 1H), 7.81 (d, *J* = 8.2 Hz, 2H), 7.58-7.54 (m, 2H), 7.44-7.41 (m, 2H), 7.38 (ddd, *J* = 8.7, 6.6, 0.9 Hz, 1H), 7.33 (d, *J* = 8.6 Hz, 1H), 7.29 (d, *J* = 8.0 Hz, 2H), 7.17 (ddd, *J* = 8.6, 6.6, 0.6 Hz, 1H), 2.46 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 185.5, 148.7, 145.1, 139.6, 135.1, 132.5, 132.3, 130.2, 129.5, 127.2, 127.0, 125.1, 123.9, 122.9, 120.7, 118.5, 21.9.

HRMS (ESI): Calcd for C₂₁H₁₆BrN₂O⁺ [M+H]⁺ 391.0441, found 391.0440.



(2-(4-chlorophenyl)-2H-indazol-3-yl)(p-tolyl)methanone (5e)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5e** (50 mg, 73% yield) as a white solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) δ 7.86 (d, *J* = 8.8 Hz, 1H), 7.81 (d, *J* = 8.1 Hz, 2H), 7.49 (d, *J* = 8.7 Hz, 2H), 7.41 (d, *J* = 8.7 Hz, 2H), 7.37-7.35 (m, 1H), 7.29 (dd, *J* = 18.9, 10.9 Hz, 3H), 7.20-7.12 (m, 1H), 2.46 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 185.5, 148.6, 145.0, 139.0, 135.0, 134.8, 132.4, 130.2, 129.5, 129.2, 127.2, 126.6, 125.0, 123.9, 120.6, 118.5, 21.8.

HRMS (ESI): Calcd for $C_{17}H_{19}N_2^+$ [M+H]⁺ 347.0946, found 347.0940.



(6-methoxy-2-phenyl-2H-indazol-3-yl)(p-tolyl)methanone (5f)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5f** (55 mg, 81% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.78 (d, *J* = 8.1 Hz, 2H), 7.52-7.50 (m, 2H), 7.42-7.35 (m, 3H), 7.25-7.21 (m, 3H), 7.09 (d, *J* = 1.9 Hz, 1H), 6.85 (dd, *J* = 9.2, 2.2 Hz, 1H), 3.89 (s, 3H), 2.42 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 185.7, 159.2, 149.6, 144.7, 140.5, 135.1, 132.4, 130.1, 129.4, 129.0, 128.5, 125.3, 121.4, 119.9, 119.7, 95.0, 55.3, 21.8.

HRMS (ESI): Calcd for C₂₂H₁₉N₂O₂⁺ [M+H]⁺ 343.1441, found 343.1432.



(5-bromo-2-phenyl-2H-indazol-3-yl)(p-tolyl)methanone (5g)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5g** (53 mg, 68% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.77-7.74 (m, 3H), 7.59 (d, *J* = 1.2 Hz, 1H), 7.52-7.50 (m, 2H), 7.45-7.39 (m, 4H), 7.27 (d, *J* = 8.0 Hz, 2H), 2.45 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 185.3, 146.9, 145.2, 140.2, 134.8, 132.0, 130.9, 130.1, 129.6, 129.2, 129.1, 125.3, 124.9, 122.8, 120.2, 118.8, 21.9.

HRMS (ESI): Calcd for C₂₁H₁₆BrN₂O + [M+H]⁺ 391.0441, found 391.0443.



(2-(tert-butyl)-2H-indazol-3-yl)(p-tolyl)methanone (5h)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5h** (25 mg, 43% yield) as a yellow solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.80-7.75 (m, 3H), 7.29 (d, *J* = 8.0 Hz, 2H), 7.26-7.22 (m, 1H), 6.97-6.96 (m, 2H), 2.46 (s, 3H), 1.83 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 189.1, 145.8, 145.1, 135.7, 132.0, 130.5, 129.6, 125.7, 124.1, 123.1, 120.1, 117.9, 64.1, 30.7, 21.9.

HRMS (ESI): Calcd for C₁₉H₂₁N₂O ⁺ [M+H]⁺ 293.1648, found 293.1646.



(2-cyclohexyl-2H-indazol-3-yl)(p-tolyl)methanone (5i)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5i** (29 mg, 45% yield) as a white solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.82 (d, *J* = 8.7 Hz, 1H), 7.78 (d, *J* = 8.1 Hz, 2H), 7.31 (d, *J* = 7.8 Hz, 2H), 7.29-7.25 (m, 1H), 7.06-7.05 (m, 2H), 5.15-5.07 (m, 1H), 2.48 (s, 3H), 2.20-2.11 (m, 4H), 1.94 (d, *J* = 13.2 Hz, 2H), 1.77-1.73 (m, 1H), 1.54-1.42 (m, 2H), 1.41-1.33 (m, 1H).

¹³C NMR (100 MHz, CDCl₃) δ 186.3, 147.3, 144.3, 136.2, 131.2, 130.1, 129.3, 125.7, 124.0, 123.3, 120.6, 118.3, 61.3, 33.8, 25.7, 25.4, 21.8.

HRMS (ESI): Calcd for C₂₁H₂₃N₂O⁺ [M+H]⁺ 319.1805, found 319.1797.



phenyl(2-phenyl-2H-indazol-3-yl)methanone (5j)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5j** (52 mg, 87% yield) as a yellow solid. Compound is known.

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.90-7.86 (m, 3H), 7.61 (t, *J* = 7.4 Hz, 1H), 7.55-7.52 (m, 2H), 7.48-7.36 (m, 7H), 7.18 (dd, *J* = 8.2, 7.0 Hz, 1H).

¹³C NMR (100 MHz, CDCl₃) δ 186.0, 148.6, 140.5, 137.9, 133.6, 132.3, 129.9, 129.1, 129.0, 128.7, 127.1, 125.6, 125.1, 124.1, 120.6, 118.6.

HRMS (ESI): Calcd for $C_{17}H_{19}N_2^+[M+H]^+$ 299.1179, found 299.1171.



(4-methoxyphenyl)(2-phenyl-2H-indazol-3-yl)methanone(5k)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5k** (33 mg, 51% yield) as a white solid. Compound is known.

¹**H NMR** (400 MHz, CDCl₃) δ 7.91-7.86 (m, 3H), 7.56-7.54 (m, 2H), 7.45-7.36 (m, 5H), 7.19-7.15 (m, 1H), 6.95 (d, *J* = 8.5 Hz, 2H), 3.89 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 184.7, 164.1, 148.5, 140.5, 132.6, 132.5, 130.5, 129.1, 128.8, 126.9, 125.4, 124.6, 123.7, 120.6, 118.4, 113.9, 55.6.

HRMS (ESI): Calcd for $C_{24}H_{17}N_2O^+$ [M+H]⁺ 329.1285, found 329.1276.



(4-bromophenyl)(2-phenyl-2H-indazol-3-yl)methanone (5l)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5l** (41 mg, 55% yield) as a yellow solid. Compound is known.

¹**H** NMR (400 MHz, CDCl₃) δ 7.88 (dd, J = 8.5, 1.2 Hz, 1H), 7.72-7.70 (m, 2H), 7.60-7.57 (m, 2H), 7.52-7.50 (m, 2H), 7.43-7.36 (m, 5H), 7.21-7.17 (m, 1H).

¹³C NMR (100 MHz, CDCl₃) δ 184.7, 148.6, 140.4, 136.5, 132.0, 131.8, 131.3, 129.1, 129.1, 128.8, 127.1, 125.5, 125.3, 124.0, 120.3, 118.7.

HRMS (ESI): Calcd for C₂₀H₁₄BrN₂O + [M+H]⁺ 377.0284, found 377.0278.



naphthalen-2-yl(2-phenyl-2H-indazol-3-yl)methanone (5m)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5m** (49 mg, 70% yield) as a white solid. Compound is known.

¹**H** NMR (400 MHz, CDCl₃) δ 8.40 (s, 1H), 7.99-7.85 (m, 5H), 7.63-7.55 (m, 4H), 7.41-7.36 (m, 5H), 7.15 (dd, J = 8.2, 6.8 Hz, 1H).

¹³C NMR (100 MHz, CDCl₃) δ 185.9, 148.6, 140.6, 135.9, 135.1, 132.5, 132.5, 132.3, 129.6, 129.1, 129.0, 129.0, 128.8, 127.9, 127.1, 127.1, 125.5, 125.1, 125.0, 124.1, 120.6, 118.6.

HRMS (ESI): Calcd for $C_{24}H_{17}N_2O^+$ [M+H]⁺ 349.1335, found 349.1326.



(2-phenyl-2H-indazol-3-yl)(thiophen-2-yl)methanone (5n)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **5n** (47 mg, 78% yield) as a yellow solid. Compound is known.

¹**H NMR** (400 MHz, CDCl₃) δ 7.88 (d, J = 8.8 Hz, 1H), 7.76 (dd, J = 4.9, 0.7 Hz, 1H), 7.66-7.63 (m, 2H), 7.58-7.56 (m, 2H), 7.47-7.37(m, 4H), 7.24-7.20 (m, 1H),

7.13-7.11 (m, 1H).

¹³C NMR (100 MHz, CDCl₃) δ 177.9, 148.6, 144.2, 140.4, 135.6, 135.5, 132.1, 129.2, 129.0, 128.3, 127.1, 125.4, 124.9, 123.6, 120.4, 118.5.

HRMS (ESI): Calcd for $C_{17}H_{19}N_2^+$ [M+H]⁺ 305.0743, found 305.0735.



((1r,3R,5S)-adamantan-1-yl)(2-phenyl-2H-indazol-3-yl)methanone(50)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=15:1 as the eluent) to give **50** (28 mg, 40% yield) as a white solid. New compounds.

¹**H NMR** (400 MHz, CDCl₃) *δ* 7.78 (d, *J* = 8.8 Hz, 1H), 7.60-7.55 (m, 3H), 7.52-7.43 (m, 3H), 7.37-7.33 (m, 1H), 7.18-7.14 (m, 1H), 1.92 (s, 3H), 1.68 (d, *J* = 2.2 Hz, 6H), 1.65-1.62 (m, 3H), 1.54-1.51 (m, 3H).

¹³**C NMR** (100 MHz, CDCl₃) δ 206.1, 148.5, 141.1, 133.9, 129.4, 129.0, 127.0, 125.0, 123.3, 121.7, 120.1, 117.9, 48.2, 38.1, 36.1, 27.7.

HRMS (ESI): Calcd for C₂₄H₂₅N₂O⁺ [M+H]⁺ 357.1961, found 357.1954.

4. Scale-up Synthesis



The reaction vessel was charged with 2-phenyl-2H-indazole (**1a**, 5.15 mmol, 1 g), diethyl 4-isopropyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (**2a**, 15.45 mmol, 4.56 g), Na₂S₂O₈ (3.0 equiv., 3.68 g), AgNO₃ (30 mol%, 262.4 mg) and TFA (2.0 equiv., 1.17 g) in *i*-PrOH /H₂O (1:1, 104 mL), and the reaction mixture was stirred under nitrogen atmosphere at room temperature for 2 h. After completion, the reaction mixture was quenched with 100 mL water/ethyl acetate (1:1). Then the reaction mixture was extracted with ethyl acetate and the organic phase was washed with Brine, dried over anhydrous Na₂SO₄. After evaporating the solvent under reduced pressure, the crude product was purified by column chromatography using petroleum ether/ethyl acetate as the eluents. The product was obtained as a yellow solid (1.08 g, 88%).



The reaction vessel was charged with 2*H*-indazole (**1a**, 5.15 mmol, 1g), diethyl 2,6-dimethyl-4-(4-methylbenzoyl)-1,4-dihydropyridine-3,5-dicarboxylate (**4a**, 15.45 mmol, 5.74 g), Na₂S₂O₈ (3.0 equiv., 3.68 g), AgNO₃ (40 mol%, 350 mg) and TFA (3.0 equiv., 1.76 g) in acetone/H₂O (1:1, 104 mL), and the reaction mixture was stirred under nitrogen atmosphere at 25 °C for 4 hours. After completion, the reaction mixture was quenched with 100 mL water/ethyl acetate (1:1). Then the reaction mixture was extracted with ethyl acetate and the organic phase was washed with Brine, dried over anhydrous Na₂SO₄. After evaporating the solvent under reduced pressure, the crude product was purified by column chromatography using petroleum ether/ethyl acetate as the eluents. The product was obtained as a yellow solid (1.39 g, 86%).

5. Synthesis of Bioactive Molecules



The reaction vessel was charged with 2-(3-methoxyphenyl)-2H-indazole (**1v**, 0.2 mmol, 44.9 mg), diethyl 4-(3-hydroxybenzoyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (0.6 mmol, 224 mg), Na₂S₂O₈ (3.0 equiv., 143 mg), AgNO₃ (40 mol%, 14 mg) and TFA (3.0 equiv., 68 mg) in acetone/H₂O (1:1, 4 mL), and the reaction mixture was stirred under nitrogen atmosphere at 25 °C for 4 hours. After completion, the reaction mixture was quenched with 20 mL water/ethyl acetate (1:1). Then the reaction mixture was extracted with ethyl acetate and the organic phase was washed with Brine, dried over anhydrous Na₂SO₄. After evaporating the solvent under reduced pressure, the crude product was purified by column chromatography using petroleum ether/ethyl acetate as the eluents. The product was obtained as a yellow solid (34.4 mg, 50%).



(3-hydroxyphenyl)(2-(3-methoxyphenyl)-2H-indazol-3-yl)methanone (5v)

Following the general procedure B, the crude product was purified by silica gel flash chromatography (PE: EA=10:1 as the eluent) to give **5v** (34mg, 50% yield) as a white solid

¹**H** NMR (400 MHz, DMSO) δ 9.87 (s, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.45-7.22 (m,

6H), 7.18-7.15 (m, 2H), 7.10-7.02 (m, 3H), 3.78 (s, 3H).

¹³C NMR (100 MHz, DMSO) δ 185.5, 159.4, 157.5, 147.7, 141.1, 138.5, 132.2, 129.9, 127.1, 125.0, 123.3, 120.9, 120.5, 120.2, 118.1, 117.6, 115.4, 114.7, 111.1, 55.4.

HRMS (ESI): Calcd for $C_{21}H_{17}N_2O_3^+[M+H]^+$ 345.1234, found 345.1226.



6-bromo-3-cyclohexyl-2-phenyl-2H-indazole (3w)

Following the general procedure A, the crude product was purified by silica gel flash chromatography (PE: EA=20:1 as the eluent) to give 3w (34mg, 48% yield) as a white solid

¹H NMR (400 MHz, CDCl₃) δ 7.87 (s, 1H), 7.73 (d, J = 9.0 Hz, 1H), 7.57-7.50 (m, 3H), 7.46-7.44 (m, 2H), 7.11 (dd, J = 9.0, 1.5 Hz, 1H), 2.98-2.90 (m, 1H), 1.93-1.83 (m, 6H), 1.78-1.74 (m, 1H), 1.39-1.19 (m, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 149.5, 141.8, 139.8, 129.2, 129.2, 126.3, 124.2, 122.6, 120.4, 120.1, 118.1, 37.2, 32.6, 26.4, 25.7.

HRMS (ESI): Calcd for C₁₉H₂₀BrN₂⁺[M+H]⁺ 355.0804, found 355.0797.





3-cyclohexyl-2-phenyl-2H-indazole-6-carboxylic acid (3x)^[7]

A 10 mL Schlenk tube equipped with a stir bar was charged with $(CO_2H \cdot H_2O)_2$ (3 equiv.), Pd(OAc)₂ (40 mol%), xantphos (5 mol%), 6-bromo-3-cyclohexyl-2-phenyl-2H-indazole (**3x**) (0.2 mmol), Ac₂O (3 equiv.), DIPEA(3 equiv.), and DMF (1.0 mL) in air. The tube was quickly sealed with a Teflon® high pressure valve, frozen in liquid nitrogen, evacuated and backfilled with N₂ (5 times). After the reaction mixture was stirred in a preheated oil bath (100 °C) for 6 h, it was allowed to cool down to room temperature. Then the reaction mixture was extracted with ethyl acetate and the organic phase was washed with Brine, dried over anhydrous Na₂SO₄. the crude product was purified by silica gel flash chromatography (PE: EA=5:1 to EA as the eluent) , then recrystallization with CHCl₃ to give **3x** (52 mg, 81% yield) as a white solid.

¹**H NMR** (400 MHz, DMSO) *δ* 12.97 (br, 1H), 8.29 (s, 1H), 8.06 (d, *J* = 8.9 Hz, 1H), 7.65-7.56 (m, 6H), 2.92-2.87 (m, 1H), 1.97-1.91 (m, 4H), 1.80-1.77 (m, 2H), 1.68-1.65 (m, 1H), 1.42-1.33 (m, 1H), 1.20-1.17 (m, 2H).

¹³C NMR (100 MHz, DMSO) δ 167.6, 147.3, 141.2, 139.4, 129.4, 129.3, 128.6,

126.3, 121.6, 120.7, 120.5, 119.8, 36.7, 31.7, 26.1, 25.0.

HRMS (ESI): Calcd for C₂₀H₂₁N₂O₂⁺ [M+H]⁺ 321.1598, found 321.1591.

6. Control Experiment



The reaction vessel was charged with 2-phenyl-2H-indazole (**1a**, 0.2 mmol), diethyl 4-isopropyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (**2a**, 0.6 mmol, 177 mg), Na₂S₂O₈ (3.0 equiv., 143 mg), AgNO₃ (30 mol%, 10 mg), TEMPO (4.0 equiv., 125 mg) and TFA (2.0 equiv., 46 mg) in *i*-PrOH /H₂O (1:1, 4 mL), and the reaction mixture was stirred under nitrogen atmosphere at room temperature for 2 h.



HRMS (ESI): Calcd for C₁₂H₂₆NO⁺ [M+H]⁺ 200.2009, found 200.2015.

7. References

- [1] N. E. Genung, L. Wei, G. E. Aspnes, Org. Lett. 2014, 16, 3114-3117.
- [2] G. Bogonda, H. Y. Kim, K. Oh, Org. Lett. 2018, 20, 2711-2715.
- [3] A. Gutiérrez-Bonet, C. Remeur, J. K. Matsui, G. A. Molander, J. Am. Chem. Soc.
 2017, 139, 12251-12258.
- [4] J. P. Phelan, S. B. Lang, J. Sim, S. Berritt, A. J. Peat, K. Billings, L. Fan, G. A.

Molander, J. Am. Chem. Soc. 2019, 141, 3723-3732.

- [5] G. X. Li, R. Chen, L. Wu, Q. Q. Fu, X. M. Zhang, Z. Tang, Angew. Chem. Int. Ed. 2013, 52, 8432-8436.
- [6] G. Goti, B. Bieszczad, A. Vega-Peñaloza, P. Melchiorre, *Angew. Chem. Int. Ed.*2019, 58, 1213-1217.
- [7] C. D. Shao, A. L. Lu, X. L. Wang, B. Zhou, X. H. Guan, Y. H. Zhang, Org. Biomol. Chem. 2017, 15, 5033-5040.



8. ¹H NMR and ¹³C NMR Spectra of the Products




3c







3f











3k











3p





3q







3t



3u



5a





5c





5e





5g



5h



5j

5k

7,8983 7,728951 7,728951 7,728951 7,72891 7,728159 7,727120 7,75914 7,5914 7,5914 7,5914 7,5914 7,5914 7,5914 7,5914 7,5914 7,5914 7,5914 7,5914 7,5915 7,4915 7,4915 7,4915 7,4915 7,4913 7,4013 7,7015 7,705 7,70



